An <i>In Silico</i> Computational Screening of Bioactive Molecules Retrieved from Selected Herbs against the Target Breast Cancer Gene 1
Background: Breast cancer, one of the most prevalent cancers globally, affects millions of women each year, with increasing incidence rates. Conventional treatments often have limitations, including side effects and drug resistance. Molecular docking of bioactive compounds from medicinal herbs offers a novel approach to identifying natural inhibitors that target specific cancer genes, potentially leading to more effective, less toxic therapies. Objective: This study aims to analyse the molecular docking of bioactive molecules in the raw drugs of selective herbs against Breast Cancer Gene 1 by in silico computational screening. Methodology: From the literature survey, nine major bioactive compounds having a higher therapeutic value from the raw drugs of the selected herbs had been selected as ligands and Breast Cancer Gene 1 (PDB ID: 4Y2G) as a potential protein drug target for in silico molecular docking analysis using Autodock 4 software. Results: Among the 9 selected bio-active molecules in the selected 8 herbs, the results showed that the estimated binding energies in kcal/mol of the selected compounds towards the target Breast Cancer Gene 1 with its acidic and polar residues were as follows: Friedelin -8.21, Hinokiflavone -6.89, Curcumin -6.25, Picein -6.20, Bhilawanol A -5.93, Tinosporide -5.79, Kaempferol -5.47, β-pinene -4.02, Plumbagin -4.01. The ligand interactions with the target revealed the following scores in ascending order: β-pinene scored four, Plumbagin-five, Kaempferol-five, Hinokiflavone-six, Friedelin-seven, Tinosporide-eight, Curcumin-eight, Picein-eight, and Bhilawanol A-nine. Bhilawanol A exhibits the strongest interaction. Conclusion: Molecular docking studies of bioactive compounds derived from the raw drugs of the selected herbs suggest their potential as inhibitory potential of the Breast Cancer Gene 1, which is involved in the development of breast cancer. Major Findings: The study identified Bhilawanol A as the most promising bioactive c